
AnPac Bio-Medical Science Co., Ltd. ANPC
Country |
|
IPO year |
2020 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBAL |
Shares |
38.2 M |
Market Cap[1] |
$ 28.1 M |
EBITDA (LTM) |
$ -297 M |
P/E (LTM) |
- |
P/S (LTM) |
0.7 |
EPS (LTM) |
-13.99 |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
|
Midatech Pharma plc
MTP
|
- | -18.52 % | $ 27.3 M | Nasdaq Global Select Market | ||
|
Tiziana Life Sciences PLC
TLSA
|
$ 0.61 | -8.44 % | $ 65.1 M | Nasdaq Global Market | ||
|
MorphoSys AG
MOR
|
- | 2.43 % | $ 254 M | Nasdaq Global Select Market | ||
|
Affimed N.V.
AFMD
|
- | -34.95 % | $ 21.5 M | Nasdaq Global Select Market,SPB | ||
|
Celyad Oncology SA
CYAD
|
- | - | $ 12.5 M | Nasdaq Global Market | ||
|
Seer
SEER
|
$ 1.62 | -3.57 % | $ 89.7 M | Nasdaq Global Select Market | ||
|
Gracell Biotechnologies
GRCL
|
- | - | $ 3.37 B | Nasdaq Global Select Market | ||
|
Shattuck Labs
STTK
|
$ 4.86 | -2.71 % | $ 338 M | Nasdaq Global Select Market | ||
|
Silence Therapeutics plc
SLN
|
$ 19.78 | 0.15 % | $ 2.8 B | Nasdaq Global Select Market | ||
|
Stoke Therapeutics
STOK
|
$ 27.16 | -1.98 % | $ 1.61 B | Nasdaq Global Select Market,SPB | ||
|
Sutro Biopharma
STRO
|
$ 10.08 | -5.0 % | $ 85.7 M | Nasdaq Global Select Market | ||
|
Soligenix
SNGX
|
$ 0.32 | -6.35 % | $ 1.66 M | Nasdaq Capital Market | ||
|
Teva Pharmaceutical Industries Limited
TEVA
|
$ 42.54 | -1.0 % | $ 48.7 B | NYSE | ||
|
China SXT Pharmaceuticals
SXTC
|
$ 2.99 | -3.55 % | $ 2.03 M | Nasdaq Global Select Market | ||
|
Spruce Biosciences
SPRB
|
$ 46.36 | -6.04 % | $ 35.5 M | Nasdaq Global Select Market | ||
|
Takeda Pharmaceutical Company Limited
TAK
|
$ 20.9 | -0.9 % | $ 33 B | NYSE | ||
|
Supernus Pharmaceuticals
SUPN
|
$ 28.77 | 4.15 % | $ 1.62 B | Nasdaq Global Select Market,SPB | ||
|
Galapagos NV
GLPG
|
- | - | $ 1.83 B | Nasdaq Global Select Market | ||
|
Savara
SVRA
|
$ 4.92 | -2.57 % | $ 1.09 B | Nasdaq Global Select Market | ||
|
Teligent, Inc.
TLGT
|
- | -13.85 % | $ 16.1 M | Nasdaq Global Select Market | ||
|
Viela Bio, Inc.
VIE
|
- | - | $ 2.91 B | Nasdaq Global Select Market | ||
|
TG Therapeutics
TGTX
|
$ 64.27 | 1.4 % | $ 9.28 B | Nasdaq Capital Market | ||
|
Aphria Inc.
APHA
|
- | -0.45 % | $ 4.87 B | Nasdaq Global Select Market | ||
|
Aerpio Pharmaceuticals, Inc.
ARPO
|
- | -0.90 % | $ 104 M | Nasdaq Capital Market | ||
|
Chiasma, Inc.
CHMA
|
- | -6.00 % | $ 238 M | Nasdaq Global Select Market | ||
|
Trevi Therapeutics
TRVI
|
$ 14.92 | -2.55 % | $ 2.01 B | Nasdaq Global Market | ||
|
Adamas Pharmaceuticals, Inc.
ADMS
|
- | - | $ 376 M | Nasdaq Global Market | ||
|
Cellect Biotechnology Ltd.
APOP
|
- | 0.38 % | $ 12.9 M | Nasdaq Global Select Market | ||
|
AzurRx BioPharma, Inc.
AZRX
|
- | 2.07 % | $ 34.4 M | Nasdaq Capital Market | ||
|
Cerecor Inc.
CERC
|
- | -1.68 % | $ 283 M | Nasdaq Capital Market | ||
|
Constellation Pharmaceuticals, Inc.
CNST
|
- | - | $ 1.63 B | Nasdaq Global Select Market | ||
|
Auris Medical Holding Ltd.
EARS
|
- | -1.77 % | $ 39.2 M | Nasdaq Capital Market | ||
|
Dicerna Pharmaceuticals, Inc.
DRNA
|
- | 0.34 % | $ 2.98 B | Nasdaq Global Select Market,SPB | ||
|
ERYTECH Pharma S.A.
ERYP
|
- | 1.3 % | $ 27.7 M | Nasdaq Global Select Market | ||
|
GW Pharmaceuticals plc
GWPH
|
- | - | $ 6.81 B | Nasdaq Global Select Market | ||
|
Kadmon Holdings, Inc.
KDMN
|
- | - | $ 1.7 B | Nasdaq Global Select Market | ||
|
Liminal BioSciences
LMNL
|
- | - | $ 256 M | Nasdaq Global Market | ||
|
argenx SE
ARGX
|
$ 972.42 | 1.05 % | $ 59.6 B | Nasdaq Global Select Market | ||
|
XBiotech
XBIT
|
$ 1.97 | 3.2 % | $ 60.1 M | Nasdaq Global Select Market | ||
|
Neos Therapeutics, Inc.
NEOS
|
- | -2.54 % | $ 57.2 M | Nasdaq Global Market | ||
|
Odonate Therapeutics, Inc.
ODT
|
- | -3.18 % | $ 58.5 M | Nasdaq Global Select Market | ||
|
Orphazyme A/S
ORPH
|
- | -2.25 % | $ 31.3 M | Nasdaq Global Select Market | ||
|
Osmotica Pharmaceuticals plc
OSMT
|
- | -10.74 % | $ 89.9 M | Nasdaq Global Select Market | ||
|
Pandion Therapeutics, Inc.
PAND
|
- | - | $ 1.77 B | Nasdaq Global Select Market | ||
|
Xenetic Biosciences
XBIO
|
$ 1.76 | -2.09 % | $ 2.99 M | Nasdaq Capital Market | ||
|
Viridian Therapeutics
VRDN
|
$ 30.86 | 2.22 % | $ 3.14 B | Nasdaq Capital Market | ||
|
Translate Bio, Inc.
TBIO
|
- | - | $ 2.81 B | Nasdaq Global Select Market,SPB | ||
|
Trillium Therapeutics Inc.
TRIL
|
- | - | $ 1.94 B | Nasdaq Capital Market | ||
|
Urovant Sciences Ltd.
UROV
|
- | - | $ 532 M | Nasdaq Global Select Market |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.